全球神經保護市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計神經保護市場將從 2025 年的 434.6 億美元成長到 2034 年的 857.2 億美元，2026 年至 2034 年的複合年成長率為 7.84%。

由於阿茲海默症、帕金森氏症和中風併發症等神經退化性疾病的發生率不斷上升，全球神經保護市場日益受到關注。神經科學研究投入的增加以及創新神經保護藥物臨床試驗的擴展正在推動市場成長。製藥公司正致力於研發治療方法。

成長要素包括全球人口老化、早期診斷意識的提高以及基於生物標記的檢測技術的進步。政府對神經系統疾病研究和開發的資助以及支持性的法規結構正在加速藥物研發。此外，生技公司與學術機構之間的合作也正在加速神經保護療法的創新。

未來幾年，個人化醫療和基因療法有望徹底改變神經保護領域。包括幹細胞療法和神經營養因子在內的新治療方法有望創造新的收入來源。新興國家醫療基礎設施的擴建以及患者獲得先進治療的便利性提高，將進一步增強市場的長期前景。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球神經保護市場：依藥物類型分類

• 市場分析、洞察與預測
• 自由基清除劑（抗氧化劑）
• 麩胺酸拮抗劑（抗興奮性毒性藥物）
• 細胞凋亡抑制劑
• 抗發炎藥
• 神經營養因子（NTFs）
• 金屬離子螯合劑
• 興奮劑
• 其他

第5章 全球神經保護市場：按應用分類

• 市場分析、洞察與預測
• 預防
• 治療

第6章 全球神經保護市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Eli Lilly And Company
  • AbbVie Inc
  • Dr. Reddy'S Laboratories Ltd
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Astrocyte Pharmaceuticals Inc
  • F. Hoffmann-La Roche AG
  • Biogen Inc
  • Pfizer Inc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Gilead Sciences
  • Amgen Inc

The Neuroprotection Market size is expected to reach USD 85.72 Billion in 2034 from USD 43.46 Billion (2025) growing at a CAGR of 7.84% during 2026-2034.

The Global Neuroprotection Market is gaining traction due to rising prevalence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and stroke-related complications. Increasing research investments in neuroscience and growing clinical trials for innovative neuroprotective agents are driving market expansion. Pharmaceutical companies are focusing on therapies that prevent neuronal damage and improve long-term cognitive outcomes.

Growth drivers include the aging global population, heightened awareness about early diagnosis, and advancements in biomarker-based detection techniques. Government funding for neurological research and supportive regulatory frameworks are encouraging drug development. Additionally, partnerships between biotech firms and academic institutions are accelerating innovation in neuroprotective therapies.

In the coming years, personalized medicine and gene-based therapies are expected to transform the neuroprotection landscape. Emerging treatment modalities, including stem cell therapy and neurotrophic factors, will likely create new revenue streams. Expanding healthcare infrastructure in emerging economies and improved patient access to advanced therapies will further strengthen long-term market prospects.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Free Radical Trapping Agents (Antioxidants)
• Glutamate Antagonists (Anti-excitotoxic Agents)
• Apoptosis Inhibitors
• Anti-inflammatory Agents
• Neurotrophic Factors (NTFs)
• Metal Ion Chelators
• Stimulants
• Others

By Application

• Prevention
• Treatment

COMPANIES PROFILED

• Daiichi Sankyo Company, , Eli Lilly and Company, AbbVie Inc, Dr Reddys Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Novartis AG, AstraZeneca plc, Astrocyte Pharmaceuticals Inc, F HoffmannLa Roche AG, Biogen Inc, Pfizer Inc, Johnson Johnson, Merck Co Inc, Gilead Sciences, Amgen Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEUROPROTECTION MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Free Radical Trapping Agents (Antioxidants) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Glutamate Antagonists (Anti-excitotoxic Agents) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Apoptosis Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Anti-inflammatory Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Neurotrophic Factors (NTFs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Metal Ion Chelators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Stimulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEUROPROTECTION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Prevention Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEUROPROTECTION MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Type
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Type
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Type
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Type
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Type
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL NEUROPROTECTION INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Eli Lilly And Company
  • 8.2.2 AbbVie Inc
  • 8.2.3 Dr. Reddy'S Laboratories Ltd
  • 8.2.4 Teva Pharmaceutical Industries Ltd
  • 8.2.5 Novartis AG
  • 8.2.6 AstraZeneca Plc
  • 8.2.7 Astrocyte Pharmaceuticals Inc
  • 8.2.8 F. Hoffmann-La Roche AG
  • 8.2.9 Biogen Inc
  • 8.2.10 Pfizer Inc
  • 8.2.11 Johnson & Johnson
  • 8.2.12 Merck & Co. Inc
  • 8.2.13 Gilead Sciences
  • 8.2.14 Amgen Inc